mozavaptan

aquaretic agent; vasopressin V2 receptor antagonist; structure given in first source

Also Known As:

5-dimethylamino-1-(4-(2-methylbenzoylamino)benzoyl)-2,3,4,5-tetrahydro-1H-benzazepine; N-(4-(((5RS)-5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; OPC 31260; OPC-31260; benzamide, N-(4-((5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methyl-, hydrochloride (1:1); mozavaptan hydrochloride; mozavaptane hydrochloride; physuline

Networked: 33 relevant articles (4 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - mozavaptan: 33

Experts

1.	Torres, Vicente E: 3 articles (07/2008 - 04/2005)
2.	Lankhuizen, I M: 2 articles (07/2001 - 07/2000)
3.	Saxena, P R: 2 articles (07/2001 - 07/2000)
4.	Schoemaker, R G: 2 articles (07/2001 - 07/2000)
5.	van Veghel, R: 2 articles (07/2001 - 07/2000)
6.	Gui, Yuan-Hong: 1 article (01/2020)
7.	Jiang, Zheng-Lin: 1 article (01/2020)
8.	Li, Xia: 1 article (01/2020)
9.	Liu, Gui-Zhu: 1 article (01/2020)
10.	Liu, Hong-Xia: 1 article (01/2020)

Related Diseases

1.	Inappropriate ADH Syndrome (SIADH) 06/11/2013 - "Mozavaptan was effective for improvement of hyponatraemia in this patient with Scc-GB complicated with SIADH." 12/01/1992 - "OPC-31260 is thought to be useful in the treatment of certain disorders, such as the syndrome of inappropriate secretion of ADH (SIADH)." 06/11/2013 - "Mozavaptan was used for SIADH. " 04/01/1997 - "These results indicate that OPC-31260 is an effective therapeutic agent for hyponatremia in patients with SIADH." 07/01/1993 - "Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats."
2.	Motion Sickness (Airsickness) 01/01/2020 - "The present study was designed to investigate whether the activation of the AVP-V2R-AQP2 signaling pathway in the inner ear is involved in the induction of motion sickness and whether mozavaptan, a V2R antagonist, could reduce motion sickness. " 01/01/2020 - "Therefore, our results suggest that activation of the inner ear AVP-V2R-AQP2 signaling pathway is potentially involved in the development of motion sickness; thus, mozavaptan targeting AVP V2Rs in the inner ear may provide us with a new application option to reduce motion sickness. " 01/01/2020 - "In the present study our results showed that activation of the inner ear arginine vasopressin-vaspopressin receptor 2 (V2R)-aquaporin 2 signaling pathway was potentially involved in the development of motion sickness and that blocking V2R with mozavaptan, a V2R antagonist, was much more effective in reducing motion sickness in both rat and dog; therefore, we demonstrated a new mechanism to underlie motion sickness and a new candidate drug to reduce motion sickness." 01/01/2020 - "Vestibular training, V2R antagonist mozavaptan, or PKA inhibitor H89 blunted these changes in the V2R-AQP2 pathway signaling while reducing rotatory stimulus- or DDAVP (a V2R agonist)-induced motion sickness in rats and dogs. "
3.	Hyponatremia 01/01/2016 - "The potential of these compounds as synthetic building blocks was demonstrated by the preparation of a late-stage intermediate of the hyponatremia agent, mozavaptan." 04/01/1997 - "These results indicate that OPC-31260 is an effective therapeutic agent for hyponatremia in patients with SIADH." 07/01/1993 - "These results indicate that there is dilutional hyponatremia in rats receiving dDAVP and 40 ml/day liquid diets, and that OPC-31260 is an effective therapeutic for hyponatremia associated with dDAVP-induced SIADH." 04/01/1997 - "Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)." 01/01/2012 - "The registration includes in-hospital treatment of states of hyponatremia (conivaptan, tolvaptan, mozavaptan), the two other (lixivaptan, satavaptan) are undergoing research. "
4.	Myocardial Infarction 10/01/1998 - "This study was designed to assess the effect of a nonpeptide vasopressin V1-receptor antagonist, OPC-21268, and a vasopressin V2-receptor antagonist, OPC-31260, on hemodynamics in the early phase and the late phase after myocardial infarction in rats. " 07/06/2001 - "In the present study, the vasoconstrictor and antidiuretic effects of vasopressin were examined in vivo in conscious rats with chronic myocardial infarction, in the absence or presence of the V(1a) receptor antagonist SR-49059 or the V(2) receptor antagonist OPC-31260. "
5.	Polycystic Kidney Diseases (Polycystic Kidney Disease) 04/01/2005 - "These results support the importance of cAMP in the pathogenesis of polycystic kidney disease, confirm the effectiveness of a VPV2 antagonist to be used in clinical trials for this disease, and suggest that OPC-31260 and OPC-41061 inhibit Ras/mitogen-activated protein kinase signaling in polycystic kidneys." 04/01/2005 - "Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat." 07/01/2008 - "The arginine vasopressin V2 receptor antagonists OPC-31260 and tolvaptan inhibit the development of polycystic kidney disease in cpk mice and in three animal orthologs to human autosomal recessive polycystic kidney disease (PCK rat), autosomal dominant polycystic kidney disease (Pkd2-/WS25 mice), and nephronophthisis(pcy mouse). " 05/01/2008 - "The arginine vasopressin V2 receptor antagonists OPC-31260 and tolvaptan inhibit the development of polycystic kidney disease in cpk mice and in three animal orthologs to human autosomal recessive polycystic kidney disease (PCK rat), autosomal dominant polycystic kidney disease (Pkd2/WS25 mice), and nephronophthisis (pcy mouse). "

Related Drugs and Biologics

1.	Arginine Vasopressin (Argipressin)
2.	Peptides (Polypeptides)
3.	Deamino Arginine Vasopressin (Desmopressin)
4.	Vasopressins (Vasopressin)
5.	Tolvaptan
6.	OPC 21268
7.	Aquaporin 2
8.	Messenger RNA (mRNA)
9.	relcovaptan
10.	Antidiuretic Agents

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Drug Therapy (Chemotherapy)